1. Core Transaction Structures in M&A
Corporate transactions take one of three primary forms, each with distinct legal and tax consequences. A stock purchase involves the buyer acquiring shares directly from the seller's shareholders, typically resulting in the target company remaining as a subsidiary or being integrated into the buyer's operations. An asset purchase allows the buyer to select specific assets and liabilities, leaving behind unwanted obligations. A statutory merger combines two or more entities into a single surviving corporation through a formal process governed by state corporate law.
The choice of structure affects liability exposure, tax treatment, and post-closing operations. In a stock deal, the buyer assumes all liabilities unless contractually carved out, whereas an asset transaction permits the buyer to avoid most historical liabilities. Statutory mergers offer operational efficiency but require careful attention to successor liability rules.
2. Due Diligence and Risk Allocation
Before any transaction closes, both parties conduct extensive due diligence to identify assets, liabilities, contracts, regulatory compliance gaps, and litigation exposure. The buyer's counsel reviews corporate records, financial statements, material contracts, intellectual property registrations, employment agreements, and environmental or regulatory compliance documentation.
Risk allocation between buyer and seller is memorialized in the purchase agreement through representations, warranties, covenants, and indemnification provisions. Representations address the accuracy of financial information, title to assets, absence of undisclosed liabilities, and regulatory compliance. Warranties typically survive closing for twelve to twenty-four months, during which the buyer may assert claims for breach. Indemnification caps, baskets (minimum loss thresholds), and escrow holdbacks protect the seller against exposure while ensuring the buyer has recourse for material breaches discovered post-closing.
New York Practice and Escrow Mechanics
In New York M&A transactions, escrow arrangements are commonplace and typically enforce indemnification obligations through a neutral third-party stakeholder. The purchase agreement specifies the escrow percentage, usually ten to twenty percent of the purchase price, held for the indemnification period. New York courts examine escrow release mechanics closely when disputes arise, requiring clear contractual language defining the trigger for release and the dispute resolution process. Claims must be asserted before the escrow period expires; missing the deadline often results in loss of recourse regardless of the merits of the underlying claim.
3. Regulatory Approval and Antitrust Considerations
Depending on transaction size and industry, regulatory approval may be required before closing. The Hart-Scott-Rodino Act requires parties to file a Premerger Notification Form with the Federal Trade Commission and Department of Justice when transaction value exceeds statutory thresholds. The reviewing agencies examine whether the combination would substantially lessen competition in any relevant market, and may impose conditions, request additional information, or challenge the transaction in court.
Industry-specific regulators also impose filing requirements. Hospital mergers and acquisitions require approval from state health departments and the Centers for Medicare and Medicaid Services. Pharmacy mergers and acquisitions face scrutiny from state pharmacy boards and the Drug Enforcement Administration regarding controlled substance handling. Failure to obtain required regulatory approval can render a transaction void or subject parties to civil penalties.
Antitrust Risk Factors and Timing
The FTC and DOJ focus on market concentration, barriers to entry, and competitive effects. Transactions in concentrated industries or involving direct competitors face higher scrutiny. Parties must file premerger notifications thirty days before closing, and the reviewing agencies may request additional information, which extends the review period. Most purchase agreements include a regulatory condition that permits either party to walk away if approval is not obtained by a specified date.
4. Shareholder Approval and Fiduciary Duties
In most mergers and acquisitions, corporate law requires shareholder approval, typically by majority vote at a stockholder meeting. The board of directors has a fiduciary duty to act in the best interests of shareholders and must disclose material information about the transaction, including the purchase price, deal structure, and any conflicts of interest. The board may establish a special committee of independent directors to negotiate the transaction, which reduces the risk of shareholder litigation.
Shareholders retain the right to dissent and seek appraisal of their shares in certain statutory merger contexts. The appraisal process can be time-consuming and costly, and the court's valuation may exceed or fall short of the negotiated purchase price.
5. Closing Conditions and Post-Closing Disputes
A transaction typically closes only when specified conditions are satisfied, including accuracy of representations and warranties at closing, receipt of third-party consents, regulatory approvals, and absence of material adverse change. If closing conditions are not met by the specified deadline, either party may terminate the agreement, subject to any walk-away fees specified in the contract.
Post-closing, disputes frequently arise over alleged breaches of representations, warranties, or covenants. The purchase agreement typically specifies the governing law and dispute resolution mechanism, whether litigation, arbitration, or negotiation. The survival period for representations is critical; once the survival period expires, the indemnified party loses the right to assert breach claims. Careful documentation of claims within the survival period, including written notice to the indemnifying party and detailed factual support, is essential to preserve remedies.
| Transaction Phase | Key Steps | Primary Risk |
|---|---|---|
| Negotiation | Parties agree on price, structure, and basic terms | Deal termination if parties cannot agree on material terms |
| Due Diligence | Buyer reviews seller's records, financial statements, and contracts | Undisclosed liabilities or regulatory violations emerge |
| Purchase Agreement | Parties finalize representations, warranties, and indemnification | Disputes over risk allocation and survival periods delay deal |
| Regulatory Approval | Filing with FTC or industry-specific agencies | Approval denial or unacceptable conditions |
| Shareholder Approval | Board recommendation and stockholder vote | Shareholder litigation or vote failure |
| Closing | Parties satisfy conditions and exchange consideration | Breach of closing condition or material adverse change |
| Post-Closing | Indemnification claims asserted within survival period | Claims asserted after survival period expires |
Mergers and acquisitions involve complex legal, tax, and operational considerations that require careful planning and execution. The transaction structure, due diligence process, regulatory pathway, and dispute resolution mechanisms all shape the ultimate success and cost of the deal. Parties should document all material facts, preserve evidence of compliance and representations accuracy throughout the transaction lifecycle, and ensure that closing conditions are satisfied and documented before funds are exchanged. The survival period for representations is not indefinite; claims must be asserted within the contractual window, and the indemnifying party's obligation to respond ends once that period expires. Reviewing the purchase agreement's indemnification caps, baskets, escrow mechanics, and dispute procedures before closing ensures that both parties understand their post-closing remedies and the practical constraints on asserting or defending breach claims.
26 May, 2026
